ESG Report 2025

55 Diabetes CKD UBT251 Injection Demodex Blepharitis LB2149 Fungal Infection LB2332 Type A / B Influenza Mabrasvir Tablets Insulin Degludec / Liraglutide Injection Diabetes Moderate to severe Atopic Dermatitis Diabetes Conjunctivitis Insulin Degludec and Insulin Aspart Injection TUL01101Tablets UBT251 Injection Olopatadine Hydrochloride Eye Drops Hyperlipemia LB2237 Bacterial Infection LB2343 Rheumatoid Arthritis TUL01101 Tablets Overweight / Obesity Semaglutide Injection MASH UBT251 Injection Atopic Dermatitis Clenbuterol Ointment Diabetic Nephropathy Finerenone Tablets Atopic Dermatitis Overweight / Obesity Male Dysfunction Tadalafil Tablets Semaglutide Injection Diabetes Acetylcysteine Effervescent Tablets Respiratory Infection Xerophthalmia Sodium Hyaluronate Eye Drops TUL01101Ointment UBT251 Injection Acute Lung Injury , etc . Sivelestat Sodium for injection Hyperuricemia and Gout Dolutegravir Tablets Osteoporosis Alendronate Sodium Vitamin D3 Tablets Dietary Supplements Multi - Vitamin Tablets Fat Loss and Muscle Gain LB2249 IgA Nephropathy TUL321 Capsules Xerophthalmia TUL12101 Eye Drops R & D Pipeline Class I New Drug Progress in China Progress in the U . S . Overweight / Obesity UBT37034 Approved Diabetes UBT38006 Hyperlipoproteinemia , etc . Lp ( a ) Hypolipidemic Drug Diabetes ＆ Obesity UBT48128 Moderate to severe eczema , asthma UBT506 Vitiligo , SLE , etc Interleukin - 2 Fusion Protein Clinical Phase III Pre- Clinical IND NDA OSA UBT251 Injection Overweight / Obesity UBT37034 Bacterial Infection TUL108 for Injection Approved Bacterial Infection TUL108 for Injection Osteoporosis Romosozumab Injection Approved Moderate to severe eczema , asthma Dupilumab ALI , ARDS , etc . UBT49003 Chronic hypoparathyroidism Eneboparatide Injection Clinical Phase II Clinical Phase I The United Laboratories International Holdings Limited 2025 Environmental, Social and Governance Report